Denti.AI, a leading company in dental pathology detection using Artificial Intelligence (AI), has recently obtained FDA clearance for its latest product, Denti.AI Detect. This revolutionary imaging solution is specifically designed to aid dental professionals in identifying common dental diseases, such as caries, periapical lesions, and bone loss, by utilizing dental x-rays. Clinical studies involving a group of dentists have shown that Denti.AI Detect significantly enhances disease detection, resulting in 26% more treatment opportunities.
Previously, Denti.AI had received FDA clearance for its product, Denti.AI Auto-Chart, which automates the process of creating odontogram charts for various dental restorations, root canals, implants, crowns, and missing teeth. With the integration of Denti.AI Detect and Auto-Chart, dental professionals can now benefit from improved disease charting and treatment plan coding within multiple integrated Practice Management Systems (PMS). This integration aims to streamline dental practice workflows and enhance patient care.
A notable achievement for Denti.AI Detect is its FDA clearance for disease detection on panoramic images, making it the first company in the dental AI industry to reach this milestone. In fact, Denti.AI is the sole dental AI company with FDA clearance for the three major dental concerns: caries, periapical radiolucencies, and bone levels. This accomplishment signifies a significant advancement in dental technology.
The effectiveness of Denti.AI Detect in uncovering missed diseases has been highly praised by Dr. Edward Gelfand, a dentist who owns over 30 dental practices and is a partner of the largest Canadian DSO. Dr. Gelfand emphasizes that the tool not only identifies treatment opportunities but also plays a crucial role in patient education. Other dental professionals, including Dr. Jonathan B. Levine of JBL NYC, have also expressed their positive experiences with Denti.AI Detect, describing it as invaluable.
Prior to receiving FDA clearance, Denti.AI Detect was already licensed by Canada Health and widely used in dental practices across Canada, demonstrating its practicality and reliability. Dmitry Tuzoff, the founder and CEO of Denti.AI, acknowledges the dedication of the team behind the development of Denti.AI Detect and highlights the significance of the product’s introduction of panoramic imaging technology.
To mark the launch of Denti.AI Detect, the company is offering special pricing terms for the product in combination with Denti.AI Auto-Chart until the end of the year. Interested individuals or parties can take advantage of this opportunity by completing a form on the Denti.AI website. This limited-time offer provides an excellent chance for dental professionals to enhance their practice with cutting-edge technology.